Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Mechanisms in fluid retention - Towards a mutual concept

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. The age-related reduction in cerebral blood flow affects vertebral artery more than internal carotid artery blood flow

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Myocardial perfusion assessed with cardiac computed tomography in women without coronary heart disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Validation of non-invasive haemodynamic methods in patients with liver disease: the Finometer and the Task Force Monitor

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cholesteryl ester storage disease of clinical and genetic characterisation: A case report and review of literature

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE: Non-alcoholic fatty liver disease (NAFLD) affects about 25% of the population worldwide. NAFLD may be viewed as the hepatological manifestation of metabolic syndrome. Patients with metabolic syndrome due to diabetes or obesity have an increased risk of cardiovascular disease. This narrative review describes cardiometabolic effects of antidiabetic drugs in NAFLD.

METHODS: We conducted a systematic search in PubMed and manually scanned bibliographies in trial databases and reference lists in relevant articles.

RESULTS: Heart disease is the leading cause of death in NAFLD. Conversely, NAFLD is an independent cardiovascular risk factor in patients suffering from metabolic syndrome. NAFLD is associated with markers of atherosclerosis, and patients have increased risk of ischaemic heart disease. Additionally, patients with NAFLD have increased risk of cardiac dysfunction and heart failure. There are no randomized controlled trials showing clear effects of medical treatment on clinical outcomes in patients with NAFLD. However, based on evidence from small trials and extrapolation from trials evaluating patients with type 2 diabetes, some antidiabetic drugs may be beneficial on cardiovascular function in patients with NAFLD.

CONCLUSION: At present, there is promising evidence of a potential effect of antidiabetic drugs for patients with NAFLD. Future studies should address the treatment of NAFLD and the liver-related consequences but also aim at improving the cardiometabolic outcomes.

OriginalsprogEngelsk
TidsskriftClinical Physiology and Functional Imaging
Vol/bind39
Udgave nummer2
Sider (fra-til)122-127
ISSN1475-0961
DOI
StatusUdgivet - 29 maj 2018

ID: 53971084